DA
EPZM

Duality Advisers’s Epizyme, Inc EPZM Stock Holding History

Duality Advisers’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-133,513
Closed -$684K – 731
2021
Q3 		$684K Buy
133,513
+40,257
+43% +$244K 0.05% 404
2021
Q2 		$775K Buy
+93,256
New +$786K 0.07% 375
2020
Q4 		– Sell
-17,920
Closed -$214K – 774
2020
Q3 		$214K Buy
+17,920
New +$240K 0.01% 553

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Duality Advisers's EPZM Position: Q4 2021 in Review

Duality Advisers sold out of Epizyme, Inc (EPZM) in Q4 2021, closing a stake of 133,513 shares — an estimated $684K sold.

Duality Advisers first reported a position in EPZM in Q3 2020 and held it in 3 quarters. The position peaked at $775K in Q2 2021. 132 funds tracked by Wall St. Rank hold EPZM as of Q4 2021.

  • Duality Advisers reported no remaining Epizyme, Inc position as of Q4 2021 after selling out during the quarter.
  • Duality Advisers sold 133,513 Epizyme, Inc shares in Q4 2021, an estimated $684K.
  • Duality Advisers first reported a position in Epizyme, Inc in Q3 2020 and held it in 3 quarters.
  • Duality Advisers's Epizyme, Inc position peaked at $775K in Q2 2021.
  • 132 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.